

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	10,575,049	
				Filing Date	April 5, 2006	
				First Named Inventor	David De Kretser	
				Art Unit	1644	
Examiner Name	Maher M. Haddad					
Sheet	9	of	13	Attorney Docket Number	PARA003US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	67	SUGIYAMA M., et al., "Expression of activin A is increased in cirrhotic and fibrotic rat livers," <i>Gastroenterology</i> , 114(3):550-558 (1998)	
	68	TAKABE K., et al., "Recombinant adenovirus vector encoding follistatin: A potential tool to stimulate liver regeneration," AASLD Abstract No. 351 from <i>Hepatology</i> , October 1999	
	69	THOMAS T., et al., "Inhibins, activins, and follistatins: Expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia," <i>The Prostate</i> , 34(1): 34-43 (1998)	
	70	"Ulcerative Colitis," From National Institute of Diabetes and Digestive and Kidney Diseases (NIH Publication No. 95-1597, April 1992)	
	71	WANG E., et al., "Identification of naturally occurring follistatin complexes in human biological fluids," <i>Bioi. Reprod.</i> , 60:8-13 (1999)	
	72	WEBSITE: "Facts about pulmonary fibrosis and interstitial lung disease," American Lung Association website, originally www.lungusa.org/diseases/pulmfibrosis on 7 November 2000 - enclosed version downloaded from http://209.208.158.222/diseases/pulmfibrosis.html on 1 July 2004	
	73	WEBSITE: NADEL, M., "Crohn's Disease (Granulomatous Ileitis and Colitis)", Internet site: http://155.37.5.42/TMGEN/67062160.htm on 6 December 2000 (enclosed copy downloaded on 25 June 2004)	
	74	YASUDA H., et al., "Activin A: An autocrine inhibitor of initiation of DNA synthesis in rat hepatocytes," <i>J. Clin. Invest.</i> , 92(3):491-1496 (1993)	
	75	YASUDA H., et al., "Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats," <i>Hepatology</i> , 24(3): 636-642 (1996)	
	76	YUEN M.F., et al., "Transforming growth factor- β 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis," <i>Scand. J. Gastroenterol.</i> , 37(2):233-238 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10,575,049	
			Filing Date	April 5, 2006	
			First Named Inventor	David De Kretser	
			Art Unit	1644	
			Examiner Name	Maher M. Haddad	
Sheet	10	of	13	Attorney Docket Number	PARA003US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	77	ZHU J, et al., "Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an <i>in vivo</i> model of liver fibrosis," <i>Gastroenterology</i> , 117(5):1198-1204 (1999)	
	78	AZUMA T, et al., <i>Hepatology</i> , 34(4-2):395A (2001) (abstract)	
	79	MURATA T, et al., "Anti-activin A antibody (IgY) specifically neutralizes various activin A activities,," <i>Proc. Soc. For Exp. Biol. and Med.</i> , 211(1):100-07 (1996)	
	81	DE KRETSE DM, et al., "Activin A and Follistatin: Their role in the acute phase reaction and inflammation," <i>J. of Endocrinology</i> , 161(1):195-98 (1999)	
	82	VAN EYLL J, et al., "Shh-dependent differentiation of intestinal tissue from embryonic pancreas by Activin A," <i>J. of Cell Science</i> , 117(10):2077-86	
	83	HEDGER M, et al., "The regulation and functions of activin and follistatin in inflammation and immunity," <i>Vitam Horm</i> , 85:255-97 (2011)	
	84	LIN S-Y, et al., "Regulation of Ovarian Function by the TGF- β Superfamily and Follistatin," <i>Reproduction</i> , 126:133-48 (2003)	
	85	AMTHOR H, et al., "Follistatin Regulates Bone Morphogenetic Protein-7 (BMP-7) Activity to Stimulate Embryonic Muscle Growth," <i>Developmental Biology</i> , 243:115-27 (2002)	
	86	ZHANG Y-Q, et al., "Regulation of the Expression of Follistatin in Rat Hepatocytes," <i>Biochimica et Biophysica Acta</i> , 1354:204-10 (1997)	
	87	GAMER L, et al., "GDFI 1 is a Negative Regulator of Chondrogenesis and Myogenesis in the Developing Chick Limb," <i>Developmental Biology</i> , 229:407-20 (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10,575,049	
			Filing Date	April 5, 2006	
			First Named Inventor	David De Kretser	
			Art Unit	1644	
			Examiner Name	Maher M. Haddad	
Sheet	11	of	13	Attorney Docket Number	PARA003US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	88	PATEL K, et al., "Molecules in Focus: Follistatin," <i>The International J. of Biochemistry and Cell Biology</i> , 30:1087-93 (1998)	
	89	IEMURA S-I, et al., "Direct Binding of Follistatin to a Complex of Bone-Morphogenetic Protein and its Receptor Inhibits Ventral and Epidermal Cell Fates in Early Xenopus Embryo," <i>PNAS USA</i> , 95:9337-42 (1998)	
	90	WANKELL M, et al., "Impaired Wound Healing in Transgenic Mice Overexpressing the Activin Antagonist Follistatin in the Epidermis," <i>The EMBO Journal</i> , 20:5361-72 (2001)	
	91	USSN 10/755,545 First Office Action pages 1-15, 2007	
	92	USSN 10/755,545 Second Office Action Pages 1-17, 2008	
	93	USSN 10/755,545 Third Office Action Pages 1-26, 2008	
	94	USSN 12/399,610 First Office Action Pages 1-14, 2010	
	95	ALCOLADO R., et al., "Pathogenesis of live fibrosis," <i>Clin. Sci. (Cotch)</i> , 92(2):103-112 (1997)	
	96	GRECO B., et al., "Atherosclerotic Ischemic Renal Disease," <i>Amer. J. Kidney Diseases</i> , 9(2):167-187 (1997)	
	97	ICHIKAWA T., et al., "Transforming growth factor β and activin tonically inhibit DNA synthesis in the rat liver," <i>Hepatology</i> , 34(5): 918-925 (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Examiner Signature	/Maher Haddad/	Date Considered	09/15/2011
-----------------------	----------------	--------------------	------------

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/